Ligands for A2B Adenosine Receptor Subtype
Abstract:Adenosine is a naturally occurring nucleoside, which exerts its biological effects by interacting witha family of adenosine receptors known as A1, A2A, A2B, and A3. The A2B subtype is a low affinity receptor,which couples to stimulation of adenylyl cyclase and also leads to a rise in intracellular calcium modulatingimportant physiological processes. Adenosine exhibiting activity at this subtype is at concentrations greaterthan 10 μM. The A2B receptors show a ubiquitous distributions, the highest levels are present in cecum, colonand bladder, followed by blood vessels, mast cells and lung. Through A2B receptors, adenosine also regulatesthe growth of smooth muscle cell populations in blood vessels, cell growth, intestinal function, inhibition ofTumor Necrosis Factor (TNF-α), vascular tone, and inflammatory processes such as diarrhea and asthma.
Potent and selective adenosine agonists are the result of modifications of the parent ligand adenosine bysubstitution, namely at N6 or C2 position of the purine heterocycle or at the 5' position of the ribose moiety.5'-N-ethylcarboxamidoadenosina (NECA) is one of the most potent A2B adenosine receptor agonist. Classicalantagonists for A2B adenosine receptors are xanthine analogues obtained from multiple substitutions of theparent heterocycle by C8 substitution combined with N1 and N3 (and sometimes N7) substitutions.
Document Type: Research Article
Affiliations: Dipartimento di Scienze Farmaceutiche, Universita di Ferrara, Via Fossato di Mortara 17-19,44100 Ferrara Italy.
Publication date: December 1, 2006
More about this publication?
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.